Health-related quality of life (HRQoL) in AVAglio, a randomized, placebo (P)-controlled phase III study of bevacizumab (B), temozolomide (T) and radiotherapy (RI) in patients (pts) with newly diagnosed glioblastoma (GBM)

被引：0

作者：

Bottomley, A. ^{[1
]}

Henrikkson, R. ^{[2
,3
]}

Taphoorn, M. J. B. ^{[4
,5
]}

Cloughesy, T. ^{[6
]}

Wick, W. ^{[7
]}

Mason, W. ^{[8
]}

Saran, F. ^{[9
]}

Nishikawa, R. ^{[10
]}

Ravelo, A. ^{[11
]}

Chinot, O. L. ^{[12
]}

机构：

[1] EORTC, Qual Life Dept, Brussels, Belgium

[2] Reg Canc Ctr Stockholm, Stockholm, Sweden

[3] Umea Univ, Dept Radiotherapy & Oncol, Stockholm, Sweden

[4] Med Ctr Haaglanden Hague, Amsterdam, Netherlands

[5] Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands

[6] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA

[7] Univ Med Ctr, Dept Neurooncol, Heidelberg, Germany

[8] Univ Toronto, Princess Margaret Hosp, Fac Med, Toronto, ON, Canada

[9] Royal Marsden NHS Fdn Trust, Neurooncol Unit, Sutton, Surrey, England

[10] Saitama Med Univ, Dept Neurooncol Neurosurg, Int Med Ctr, Saitama, Japan

[11] Genentech Inc, Clin Pharmacol, San Francisco, CA 94080 USA

[12] Aix Marseille Univ, CHU Timone, AP HM, Serv Neurooncol, Marseille, France

来源：

EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3316

引用

页码：S780 / S780

页数：1

共 50 条

[1] HEALTH-RELATED QUALITY OF LIFE (HRQOL) ANALYSES IN THE AVAGLIO STUDY, A RANDOMIZED, PLACEBO-CONTROLLED PHASE III TRIAL OF BEVACIZUMAB, TEMOZOLOMIDE AND RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA
Taphoorn, Martin J. B.
Henriksson, Roger
Bottomley, Andrew
Cloughesy, Timothy
Wick, Wolfgang
Mason, Warren
Saran, Frank
Nishikawa, Ryo
Ravelo, Arliene
Hilton, Magalie
Chinot, Olivier L.
NEURO-ONCOLOGY, 2013, 15 : 232 - 232
[2] Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM)
Henriksson, Roger
Bottomley, Andrew
Mason, Warren
Saran, Frank
Wick, Wolfgang
Nishikawa, Ryo
Cloughesy, Timothy Francis
Carpentier, Antoine F.
Khe Hoang-Xuan
Kavan, Petr
Cernea, Dana
Brandes, Alba Ariela
Hilton, Magalie
Guijarro, Ana Maria Abajo
Ravelo, Arliene
Chinot, Oliver L.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[3] Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma
Taphoorn, Martin J. B.
Henriksson, Roger
Bottomley, Andrew
Cloughesy, Timothy
Wick, Wolfgang
Mason, Warren P.
Saran, Frank
Nishikawa, Ryo
Hilton, Magalie
Theodore-Oklota, Christina
Ravelo, Arliene
Chinot, Olivier L.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (19) : 2166 - +
[4] Biomarker (BM) evaluations in the phase III AVAglio study of bevacizumab (Bv) plus standard radiotherapy (RT) and temozolomide (T) for newly diagnosed glioblastoma (GBM)
Nishikawa, Ryo
Saran, Frank
Mason, Warren
Wick, Wolfgang
Cloughesy, Timothy Francis
Henriksson, Roger
Hilton, Magalie
Garcia, Josep
Vogt, Tobias
Pallaud, Celine
Chinot, Oliver L.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[5] AVAglio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.
Chinot, O. L.
Wick, W.
Saran, F.
Mason, W. P.
Henriksson, R.
Nishikawa, R.
Zeaiter, A. H.
Moore, N.
Das, A.
Cloughesy, T. F.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[6] SAFETY RESULTS FROM AVAglio, A PHASE III RANDOMIZED STUDY OF BEVACIZUMAB (BEV) PLUS STANDARD COMBINATION TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Saran, Frank
Chinot, Olivier L.
Henriksson, Roger
Mason, Warren
Wick, Wolfgang
Nishikawa, Ryo
Dahr, Sunita
Hilton, Magalie
Garcia, Josep
Cloughesy, Timothy
NEURO-ONCOLOGY, 2013, 15 : 127 - 128
[7] CORRELATION OF MOLECULAR SUBTYPES WITH OVERALL SURVIVAL (OS) IN AVAGLIO, A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB (BEV) PLUS RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Phillips, Heidi
Sandmann, Thomas
Li, Congfen
Cloughesy, Timothy
Chinot, Olivier L.
Wick, Wolfgang
Nishikawa, Ryo
Mason, Warren
Henriksson, Roger
Saran, Frank
Lai, Albert
Moore, Nicola
Hegde, Priti
Abrey, Lauren
Bourgon, Richard
Garcia, Josep
Bais, Carlos
NEURO-ONCOLOGY, 2014, 16
[8] Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).
Sim, Hao-Wen
Barnes, Elizabeth
Lwin, Zarnie
Rosenthal, Mark
Wheeler, Helen
Koh, Eng-Siew
Foote, Matthew C.
Fisher, Lauren
Leonard, Robyn
Hall, Merryn
Simes, John
Khasraw, Mustafa
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[9] Health-related quality of life (HRQOL) in patients with glioblastoma (GBM) and their caregivers in the end-of-life phase: A retrospective study.
Flechl, Birgit
Sax, Cornelia
Ackerl, Michael
Crevenna, Richard
Gaiger, Alexander
Keilani, Mohammad
Preusser, Matthias
Dieckmann, Karin
Widhalm, Georg
Oberndorfer, Stefan
Calabek, Bernadette
Reijneveld, Jaap
Sizoo, Eefje
Marosi, Christine
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[10] RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).
Gilbert, Mark R.
Dignam, James
Won, Minhee
Blumenthal, Deborah T.
Vogelbaum, Michael A.
Aldape, Kenneth D.
Colman, Howard
Chakravarti, Arnab
Jeraj, Robert
Armstrong, Terri S.
Wefel, Jeffrey Scott
Brown, Paul D.
Jaeckle, Kurt A.
Schiff, David
Atkins, James Norman
Brachman, David
Werner-Wasik, Maria
Komaki, Ritsuko
Sulman, Erik P.
Mehta, Minesh P.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 5 →